search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
News Many countries continue to overuse powerful antibiotics


Many countries are using too many powerful and inappropriate antibiotics, fuelling antibiotic resistance concerns, while millions lack access to the specific drugs they need. That is according to a major international study of antibiotic use published in The Lancet Public Health. Research led by City St George’s, University of London and University of Oxford developed the first global framework that estimates how many and which type of antibiotics each country needs to treat their infections. Antibiotics are grouped by the World Health Organization (WHO) into three categories, known as the “AWaRe” system: l ‘Access’ antibiotics are used for most common infections and have a lower resistance risk.


l ‘Watch’ antibiotics have a broader spectrum, are used for specific infections and come with higher safety and resistance concerns.


l ‘Reserve’ antibiotics are last resort antibiotics used to treat multi-drug-resistant infections.


In 2024, world leaders at the United Nations agreed that at least 70% of antibiotic use worldwide should come from the Access group by 2030. However, no method previously existed to determine the right balance of antibiotics for any individual country. To address this, researchers analysed global


data from 186 countries, territories and areas (CTAs), representing 99.8% of the global population. They grouped these countries into ‘peer groups’ based on similar infection burdens, resistance patterns, socioeconomic characteristics and healthcare access. Within each group, countries with the lowest


antibiotic use and the fewest infection-related deaths were used as benchmarks to determine what optimal antibiotic use should look like for similar countries. They then estimated optimal levels of Access, Watch and Reserve antibiotics required in each setting based on infection and resistance burdens. The team calculated that, in 2019, around 43


billion days of antibiotics were needed globally, averaging out to roughly one antibiotic course per person per year, to treat all bacterial infections appropriately. They found that 77% of global antibiotic use should be Access antibiotics, suggesting the UN’s 70% target is reasonable. Although higher-income countries currently use the most Watch and Reserve antibiotics, the study estimates that more than 80% of the world’s optimal need for these medicines lies in lower-


income countries, where infectious disease and antimicrobial resistance burdens are highest. The researchers then compared their estimates


with real-world antibiotic use data from 67 countries where this data was available. Nearly three-quarters (72%) of countries analysed were using more antibiotics in total than needed, and almost every country (99%) prescribed too many Watch antibiotics, which contribute the most to antibiotic resistance. Worryingly, 60% of countries were still using antibiotics that the WHO considers should no longer be prescribed. At the same time, 42% of countries were using


fewer Access antibiotics than estimated optimal levels, and more than half (52%) were not using enough Reserve antibiotics than estimated to be needed. This means patients with life-threatening drug-resistant infections might not be receiving the specific treatments they need. The findings suggest that many countries could


improve antibiotic use by reducing unnecessary Watch antibiotic prescribing, while increasing access to essential Access antibiotics, and ensuring availability of Reserve antibiotics for patients with highly resistant infections. The researchers highlight the need for better


monitoring of antibiotic use to identify areas of overuse and underuse, and for national targets based on local data that align antibiotic use more closely with public health and clinical need. The study was funded by the Wellcome Trust and can be viewed at: https://www.thelancet.com/ journals/lanpub/article/PIIS2468-2667(26)00103- 9/fulltext


HOW CLEAN IS YOUR SCREEN? 10:37 am


Easy Screen™ is compatible with over 320 medical devices and surfaces that require a 70% IPA approved cleaner.


EES1060 | VJT595 Some bacteria culture can


SURVIVE FOR MONTHS on the surface of a dry touchscreen device¹


workers in 1 hospital never cleaned their devices²


56% of paediatric healthcare


On average, smartphone users around the world touch their screens


2,617


More than that make up fingerprints ends up on touchscreens⁴


In a Japanese ICU study only


76% regularly cleaned their phones⁵ 10.7%of staff Touchscreen devices have


AT LEAST ONE BACTERIA culture on the screen⁶


times a day³ 80%OF BACTERIA


BACTERIA IN HEALTHCARE SETTINGS CAN INCLUDE:


Staphylococcus, Moraxella, Bacillus spp, Streptococcus spp, Acinetobacter spp, MRSA, Pantoea spp, & Enterococcus⁶


Sources available on request


Get in touch via contact@pdi-intl.com to request your FREE samples today!


October 2026 I www.clinicalservicesjournal.com 15


Warawan - stock.adobe.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68